Kyle Jenne insider trades: Ionis Pharmaceuticals (IONS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kyle reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | IONS | ↓ Sell | 4,902 | $75.17 | $368K | Direct | Apr 17, 2026 (1d) |
| Jan 16, 2026 | IONS | ↓ Sell | 1,823 | $75.96 | $138K | Direct | Jan 20, 2026 (4d) |
| Apr 16, 2025 | IONS | ↓ Sell | 3,016 | $28.36 | $86K | Direct | Apr 17, 2025 (1d) |
| Sep 22, 2020 | AKCA | ↓ Sell | 720 | $18.12 | $13K | Direct | Sep 24, 2020 (2d) |
| Mar 23, 2020 | AKCA | ↓ Sell | 779 | $11.75 | $9K | Direct | Mar 25, 2020 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other IONS insiders
Open-market trades in the last 12 months
About Kyle Jenne's insider trades
Kyle Jenne is EVP, Chf GL Pdt Str Ofcr at Ionis Pharmaceuticals (IONS). Since Mar 23, 2020, Kyle has reported no open-market purchases and 5 sales worth $615K on SEC Form 4. In the last 12 months: 2 sales ($507K).
Their filings also include grants and awards (7 filings), option exercises (3 filings), shares returned to the company (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IONS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.